LY320135 is a potent and selective CB1 receptor antagonist with neuroprotective effects; it inhibits anandamide-mediated forskolin-stimulated cAMP accumulation in CHO cells; reverses WIN55212-2-induced inhibition of calcium current (ICa) in N18 cells; prevents WIN55212-2-induced activation of Kir current in AtT-20-CB1 cells; and reduces CA1 injury induced by oxygen-glucose deprivation (OGD) in a concentration-dependent manner.